- Company unveiling innovations which harness the power of AI to
optimize the complex radiation therapy workflow and enable
personalized, more timely care for patients across the cancer care
continuum
GE HealthCare (Nasdaq: GEHC) today announced Revolution RT,i a
new radiation therapy computed tomography (CT) solution with
innovative hardware and software solutions to help increase imaging
accuracy, while simplifying simulation workflow for a more
personalized and seamless oncology care pathway experience for
clinicians and patients. The new Revolution RT is being unveiled at
the European Society for Therapeutic Radiology and Oncology (ESTRO)
2024 Congress in Glasgow, along with an updated and artificial
intelligence (AI)-enhanced version of the Intelligent Radiation
Therapy (iRT) platform, which interfaces with the Spectronic
magnetic resonance imaging (MRI) Planner. Additionally, the company
will showcase the newly acquired MIM Software portfolio, as well as
other key innovations from GE HealthCare.
One of the biggest challenges of oncology care is the complexity
of the disease — both in the many varieties of cancer, and the
disparate ways it can present in each individual patientii —
requiring diligence and personalization in diagnosis and treatment.
Additionally, treatment often requires the expertise of multiple
disciplines and experts related to specific organs and systems in
the body, resulting in potential delays to diagnosis and timely
treatment. According to research published by the British Medical
Journal (BMJ), the mortality risk increases 6-13% for every month a
diagnosis is delayediii, therefore, it is critical to streamline
the complex oncology care pathway and reduce the time from
diagnosis to treatment, ultimately leading to improved patient
outcomes.
“At GE HealthCare, we are committed to advancing the frontiers
of oncology treatment through AI-driven technologies that transform
and optimize the care continuum,” said Dr. Taha Kass-Hout, chief
technology and science officer of GE HealthCare. “Our showcase at
ESTRO this year highlights innovations that will allow clinicians
to view the patient’s anatomy with great accuracy, helping
facilitate precise tumor targeting while aiming to protect nearby
healthy tissue. By integrating these capabilities into our systems,
we create a precise, more connected, and efficient care environment
that accelerates the delivery of personalized and timely care, with
the goal of enabling better patient outcomes. This comprehensive
approach empowers clinicians around the globe to tackle the most
challenging disease states with precision and efficiency.”
GE HealthCare’s novel radiation therapy solutions, and recent
acquisition of the MIM Software portfolio, are designed to reshape
the oncology experience around the needs of providers and their
patients across the cancer care continuum:
Introducing Revolution RT
As healthcare systems around the world experience growing
volumes of radiation therapy (RT) patients, providers are looking
for a CT simulator that enables precision simulation while reducing
workflow complexity, with the goal of expediated patient
care.iv
GE HealthCare designed its new Revolution RTi with a wide-bore
CT platform and high-performance radiation therapy simulation,
diagnostic, and interventional capabilities to accommodate more
patients, and create a more streamlined standard of care.
Revolution RT includes precision radiotherapy simulation that will
help enable more accurate imaging, while improving workflow and
efficiency, and using deep learning technology to help image the
patient with accuracy.
Updated Intelligent Radiation Therapy (iRT)
At ESTRO 2024, GE HealthCare will also be showcasing the newly
updated iRT platform, which was originally launched at ESTRO 2023.
This innovative solution enables greater interoperability,
connectivity, and efficiency throughout the entirety of the
radiation oncology care continuum and includes key features such as
an integrated workflow that connects various applications into an
intuitive single interface, multi-vendor interoperability, seamless
data transfer and task automation, and a catalog of RT applications
from both GE HealthCare and third parties.
The company is unveiling multiple updates to the iRT platform,
which highlight its vendor-agnostic ecosystem:
- MR Direct (with Spectronic Medical): Spectronic Medical’s
application, which is integrated into the updated iRT, uses AI to
convert MR simulation images into an equivalent CT image that can
be used for RT dose calculation.
- Simplified Planning (with MIM): Advance interoperability with
automated context launching to simplify pre-treatment planning
steps including image viewing, segmentation, and fusion.
- InstaPlan (with RaySearch): A novel approach to treatment plan
creation while the patient is still on the simulation table. This
is a paradigm shift that can potentially reduce the time between
simulation and first radiation dose. GE HealthCare’s collaboration
with RaySearch will bring further innovation in simulation and
treatment planning workflows to support advancements in Photon,
Electron, Particle, and Brachy therapies.
- Personalization: The newly enhanced version of iRT is updated
to allow user-enabled personalization, analytics, and notification
modules.
“The key to better patient outcomes in oncology care requires
solutions that simplify and shorten an incredibly complex workflow
for providers, as well as personalize the care pathway for
patients, in order to ensure more effective care for each
individual,” said Dr. Ben Newton, general manager, Oncology at GE
HealthCare. “GE HealthCare worked closely with clinicians globally
to develop the iRT platform which streamlines the radiation therapy
pathway by connecting disparate multi-vendor application systems,
creating a vendor-agnostic ecosystem and harnessing the power of AI
to potentially reduce the critical time between treatment planning
and first treatment.”
Advancing AI and Digital Solutions for More Personalized
Oncology Radiation Therapy
GE HealthCare recently announced the acquisition close of MIM
Software and the addition of its imaging analytics and digital
workflow offerings as a part of the company’s portfolio. MIM
Software's clinical tools – paired with GE HealthCare's imaging
solutions – bring improved flexibility, automation, and efficiency
to providers. This includes the addition of MIM Software’s
radiation oncology portfolio, which is designed to provide
clinicians with complementary interoperable solutions that can help
simplify complex planning and deliver faster treatment.
Additionally, the MIM acquisition enabled the expansion of GE
HealthCare’s relationship with Elekta, a leader in precision
radiation oncology. GE HealthCare’s MIM Software portfolio will
enhance Elekta’s innovative treatment planning software which aids
in the delivery of radiation therapy through enabling precision
dose calculation. The collaboration is expected to harness MIM
Software and Elekta’s respective strengths in regional markets to
make solutions available globally.
This news complements GE HealthCare and Elekta’s existing global
collaboration agreement, which enables the two companies to provide
hospitals with a comprehensive offering across imaging and
treatment for cancer patients requiring radiation therapy.
To learn more about GE HealthCare’s latest innovations within
oncology care, please visit the ESTRO 2024 Congress booth #220 in
Glasgow from May 3-7 or visit the website here.
About GE HealthCare Technologies Inc.
GE HealthCare is a leading global medical technology,
pharmaceutical diagnostics, and digital solutions innovator,
dedicated to providing integrated solutions, services, and data
analytics to make hospitals more efficient, clinicians more
effective, therapies more precise, and patients healthier and
happier. Serving patients and providers for more than 125 years, GE
HealthCare is advancing personalized, connected, and compassionate
care, while simplifying the patient’s journey across the care
pathway. Together our Imaging, Ultrasound, Patient Care Solutions,
and Pharmaceutical Diagnostics businesses help improve patient care
from diagnosis, to therapy, to monitoring. We are a $19.6 billion
business with approximately 51,000 colleagues working to create a
world where healthcare has no limits.
Follow us on LinkedIn, X (formerly Twitter), Facebook,
Instagram, and Insights for the latest news, or visit our website
https://www.gehealthcare.com/ for more information.
_________________________
i This product is not CE Marked and cannot be placed on the
market or put into service until it has been made to comply with CE
marking. ii American Association for Cancer Research. Complexities
of Cancer Explained for Patient Benefit. Available at:
https://www.aacr.org/blog/2015/05/26/complexities-of-cancer-explained-for-patient-benefit/#:~:text=One%20of%20the%20biggest%20complexities,organs%20often%20behave%20very%20differently
. Last accessed February 2023. iii T. P. Hanna, W. D. King, S.
Thibodeau, M. Jalink, G. A. Paulin, E. Harvey-Jones, D. E.
O’Sullivan, C. M. Booth, R. Sullivan, A. Aggarwal. Mortality due to
cancer treatment delay: systematic review and meta-analysis. The
BMJ. DOI: 10.1136/bmj.m4087 iv CT Sub Segment Dashboard based on
COCIR, Ispos, EMA, JP-KPI sources.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240501248808/en/
Karin Dalsin Global Communications Director GE HealthCare
karin.dalsin@gehealthcare.com
GE HealthCare Technologies (NASDAQ:GEHC)
Historical Stock Chart
From May 2024 to Jun 2024
GE HealthCare Technologies (NASDAQ:GEHC)
Historical Stock Chart
From Jun 2023 to Jun 2024